Exact Sciences Acquires Thrive Earlier Detection

Abbott Acquires Exact Sciences in ~$21 Billion Deal to Expand Cancer Diagnostics

November 20, 2025

Healthcare Services

Abbott has agreed to acquire Exact Sciences for approximately $21 billion, valuing Exact Sciences at $105.00 per share in cash. The deal is expected to close before the end of Q2 2026, after stockholder approval and subject to regulatory clearance and other customary closing conditions.

Exact Sciences Acquires PreventionGenetics

January 9, 2022

Healthcare Services

Exact Sciences Corp. acquired PreventionGenetics, a CLIA- and ISO-accredited genetic testing laboratory based in Marshfield, Wisconsin, for $190 million (50% stock, 50% cash) to accelerate its entrance into hereditary cancer testing. PreventionGenetics reported preliminary 2021 revenue of about $36 million and ~100+ staff; Exact Sciences intends to leverage its commercial reach to expand hereditary cancer and genetic testing domestically and internationally.

Exact Sciences Acquires Paradigm Diagnostics and Viomics

March 3, 2020

Healthcare Services

Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

Veracyte Acquires Decipher Biosciences

February 3, 2021

Biotechnology

Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.